1Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a pre- dictor of outcome in a broad spectrum of patients with heart failure [ J 1. Circulation, 2006,113 ( 5 ) :671-678.
2Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008[J]. Eur Heart J, 2008,29(19) :2388-2442.
3Shlipak MG, Samak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons[J]. N Engl J Med, 2005,352(20) :2049-2060.
4Shlipak MG, Katz R, Samak MJ, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons withoutchronic kidney disease[ J]. Ann Intern Med, 2006,145 (4) :237- 246.
5Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cystatin C concen- tration as a risk factor for heart failure in older adults [ J ]. Ann In- tern Med, 2005,142 ( 7 ) :497-505.
6Shlipak MG, Katz R, Fried LF, et al. Cystatin C and mortality in elderly persons with heart failure[ J]. J Am Coll Cardiol, 2005,45 (2) :268-271.
7Stevens LA, Levey AS. Chronic kidney disease in the elderly- how to assess risk[J]. N Engl J Med, 2005,352(20):2122- 2124.
8Rule AD, Lieske JC. Cystatin C is more than GFR, and this may be a good thing[ J]. J Am Soe Nephrol, 2011,22(5 ) :795-797.
9Patel PC, Ayers CR, Murphy SA, et al. Association of Cystatin C with left ventricular structure and function: the Dallas Heart Study [J]. Circ Heart Fail, 2009,2(2) :98-104.
10Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type na- triuretic peptide assay for identifying patients at high risk cff read- mission after decompensated heart failure[ J ] J Am Coll Cardiol, 2004,43 (4) :635-641.
